Adams Revenue Grows 11% As Mucinex Sales Shift Toward Line Extensions
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics' net sales grew 11 percent to $84 million in its latest quarter as sales of single-ingredient Mucinex were cannibalized by newer extensions in the product line
You may also be interested in...
Max Strength Mucinex Sales Could Reach $70M In Debut Season – Adams
Adams Respiratory Therapeutics projects sales of its forthcoming Maximum Strength Mucinex products will eventually make up 60 percent of total Mucinex sales, the firm said April 4
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.